Combination of esomeprazole and pirfenidone enhances antifibrotic efficacy in vitro and in a mouse model of TGFβ-induced lung fibrosis

Medicine and Dentistry

• Pirfenidone 100%
• Esomeprazole 72%
• Idiopathic Pulmonary Fibrosis 45%
• Pulmonary Fibrosis 36%
• Collagen 27%
• Drug 27%
• Chemotherapeutic Agent 27%
• Cells 27%
• In Vitro 18%
• Silo-Filler's Disease 18%
• Cell Migration 18%
• Fibrosis 18%
• Lung Fibroblast 18%
• Therapeutic Procedure 18%
• Diseases 9%
• Biological Product 9%
• Etiology 9%
• Cell Proliferation 9%
• Biological Phenomena and Functions Concerning the Entire Organism 9%
• Cell Culture 9%
• Combination Therapy 9%
• Monotherapy 9%
• Gastroesophageal Reflux 9%
• Proton-Pump Inhibitor 9%
• Extracellular Matrix 9%
• Keratin 9%
• Antiproliferative Activity 9%
• Alpha Smooth Muscle Actin 9%
• Collagen Gel 9%
• Nintedanib 9%
• Differentiation 9%
• Family 9%
• Inpatient 9%
• Animal Study 9%
• Myofibroblast 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Pirfenidone 100%
• Esomeprazole 72%
• Clinical Study 54%
• Fibrosing Alveolitis 45%
• Lung Fibrosis 36%
• Collagen 27%
• Drug 27%
• Lung Disease 18%
• Mouse Model 18%
• Fibrosis 18%
• Diseases 9%
• Biological Product 9%
• Monotherapy 9%
• Proton Pump Inhibitor 9%
• Combination Therapy 9%
• Preclinical Study 9%
• Etiology 9%
• Keratin 9%
• Collagen Gel 9%
• Alpha Smooth Muscle Actin 9%
• Gastroesophageal Reflux 9%

Biochemistry, Genetics and Molecular Biology

• Esomeprazole 72%
• Collagen 27%
• Fibroblast 18%
• Cell Migration 18%
• Mouse Model 18%
• In Vivo Study 18%
• Myofibroblast 9%
• Cell Proliferation 9%
• Actin 9%
• Preclinical Study 9%
• Cell Culture 9%
• Animal Experiment 9%
• Biological Phenomena and Functions Concerning the Entire Organism 9%
• Bioinformatics 9%
• Keratin 9%
• Antiproliferative Activity 9%
• Proton Pump 9%
• Collagen Gel 9%